Seagen's Cancer Therapy Is Making It a Takeover Target
The unprofitable biotech that pioneered novel cancer agents has caught the attention of the world's largest drugmakers, who are now working to develop their own versions of the products.
An unprofitable biotech that pioneered a relatively new kind of cancer therapy has caught the
The attention of the top drugmakers in the world
On the lookout for the next big opportunity within one of the most lucrative markets in the industry.
Seagen Inc. offers three novel cancer agents, known as
antibody drug conjugates
, or ADCs—that work like a guided missile attacking tumors with toxins. Although the company's products generate around $2 billion in yearly sales and the company operates at a loss, it has a market valuation of roughly $30 billion.